CoChat

Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice

Open access
Duan, Jingjing, Wang, Zhuo, Duan, Ran, Yang, Chenxinhui, Zhao, Ruolin, Feng, Qi, Qin, Yuanyuan, Jiang, Jingwei, Gu, Shouyong, Lv, Kaiyan, Zhang, Libo, He, Bixia, Birnbaumer, Lutz, Yang, Song, Chen, Zhen, Yang, Yong · 2022 · Hepatology
Cited by 117

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Background and Aims: Globally, NAFLD is one of the most common liver disorders, with an estimated prevalence rate of more than 30% in men and 15% in women and an even higher prevalence in people with type 2 diabetes mellitus. Optimal pharmacologic therapeutic approaches for NAFLD are an urgent necessity. Approach and Results: In this study, we showed that compared with healthy controls, hepatic ACSL4 levels in patients with NAFLD were found to be elevated. Suppression of ACSL4 expression promoted mitochondrial respiration, thereby enhancing the capacity of hepatocytes to mediate β‐oxidation of fatty acids and to minimize lipid accumulation by up‐regulating peroxisome proliferator‐activated receptor coactivator‐1 alpha. Moreover, we found that abemaciclib is a potent and selective ACSL4 inhibitor, and low dose of abemaciclib significantly ameliorated most of the NAFLD symptoms in multiple NAFLD mice models. Conclusions: Therefore, inhibition of ACSL4 is a potential alternative therapeutic approach for NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.32148

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

Metadata

Authors
Duan, J., Wang, Z., Duan, R., Yang, C., Zhao, R., Feng, Q., Qin, Y., Jiang, J., Gu, S., Lv, K., Zhang, L., He, B., Birnbaumer, L., Yang, S., Chen, Z., & Yang, Y.
Venue
Hepatology
Published
2021-11-27
Volume
75
Issue
1
Pages
140-153
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W3200903411
Cited by
117
References
13
FWCI
9.34
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.